Censo Biotechnologies Ltd. have been awarded a Scottish Enterprise SMART:SCOTLAND grant for just under £100,000 to undertake an innovation project that will develop new methods to create stem cells for medical research. The grant will support scientists at the Edinburgh research facility to investigate new ways to transform human tissue, such as blood, skin or urine, into induced Pluripotent Stem Cells (iPSCs). Over the last...
Concept Life Sciences’ recent acquisition of Aquila BioMedical has quickly produced a return—an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs. Aquila will run a few in vitro, in vivo and ex vivo analyses to help Macrophage decide on the best candidate to enter the clinic. U.K.-based Macrophage targets cancer with its proprietary Esterase Sensitive Motif (ESM) technology, which delivers small-molecule drugs...
Scottish Equity Partners (SEP) announce their investment in Dotmatics, a leading global scientific informatics software company. Dotmatic’s provide enterprise solutions for pharmaceuticals, biotechnology, academia, food and beverage, oil and gas and agrochemical industries. Their solutions include tools for knowledge management, data analysis, visualisation and storage and enterprise querying and reporting. The funding from SEP will allow Dotmatics to continue to develop innovative products and customer...
Scottish Enterprise have launched Scottish Bio-Resource Support Services to provide a central source of information around Zero Waste Scotland’s new report – Biorefining Potential for Scotland. The report highlights that by utilising bio-waste materials significant value could be added to the Scottish economy. An estimated £500m – £800m could be generated for the Scottish economy by using food and drink by-products alone. With over 27...
Aberdeen based biotech firm have been nominated for the Most Innovative European Biotech SME award. NovaBiotics have developed new treatments to tackle infections, including MRSA, which are proving increasingly resistant to existing antibiotics. Over the past 13 years the company has raised £20million to finance the business and secured hundreds of patients. They believe they have made a breakthrough which will show significant results in the...
Igenza’s collaboration with Syngenta reaches technical milestones as they develop efficient manufacturing technologies for innovative crop protection products. The collaboration capitalises on the inABLE suite of capabilities in gene expression, microbial strain improvement and bioprocess scale up. Syngenta will now develop the technology further. To read the full article, click here.